Treatment of Advanced Metastatic Prostate Cancer Using Molecular-Targeted Therapy: Radioligand Lutetium-177 Prostate-Specific Membrane Antigen.

This study investigates the predicting factors of the biochemical response and survival of patients with advanced metastatic prostate cancer who underwent therapy with radioligand lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA), often referred to as [177Lu]Lu-PSMA. This study is a review of the previous literature. This study included articles published in the last 10 years in the English language. According to the literature review, treatment with [177Lu]Lu-PSMA has a positive impact on prostate-specific antigen (PSA) within the first cycle and a negative impact on lymph node metastasis. There is a plausible positive impact on PSA after multiple cycles and performance status and a negative impact on visceral metastasis. In conclusion, the reviews show that treatment with [177Lu]Lu-PSMA in patients with castration-resistant prostate cancer is beneficial in reducing PSA and metastasis.

Cureus. 2023 Apr 18*** epublish ***

Rajni Rathore, Shahid B Rangrej, Ian Kieme, Victoria Carvalho, Katie King, Yacoubou Amadou, John McKinley, Audrey Masawi

Pharmacology and Therapeutics, Saint James School of Medicine, Arnos Vale, VCT., Anatomy/Research, Saint James School of Medicine, Arnos Vale, VCT., Medical School, Saint James School of Medicine, Arnos Vale, VCT.